Expanding the biopharmaceutical industry's involvement in fighting neglected diseases.
The increasingly recognized need for new products for so-called neglected diseases, which afflict large numbers of people but have received relatively little industry investment, presents a clear example of a "strategic" corporate responsibility. Addressing neglected diseases can be important to "health diplomacy" and other national interests as well. Because industrial capabilities are essential to the development of new drugs and vaccines for these diseases, specific policy initiatives to attract more companies to do such work should also be further developed.